$91.01
-0.13-0.14%
In chiusura: -
$91.01
0.000.00%
After hour: Aug 22, 4:00 PM EDT
Comments
Loading...
Attività di insider trading
Tieni traccia delle ultime attività di insider trading ANI Pharmaceuticals. Rimani informato sui recenti acquisti, vendite e impatto sul mercato per le azioni ANI Pharmaceuticals.
Cos'è l'attività interna?
L'attività di insider trading coinvolge soggetti interni all'azienda, come dirigenti, direttori e dipendenti, impegnati in transazioni sulle azioni della propria azienda. Le transazioni di acquisto e vendita degli addetti ai lavori forniscono informazioni preziose sulla loro fiducia nelle prestazioni future dell'azienda.
Cosa stanno facendo gli ANI Pharmaceuticals Inc addetti ai lavori?
A ANI Pharmaceuticals Inc, la recente attività interna ha attirato l'attenzione. Negli ultimi 30 giorni, gli addetti ai lavori hanno riferito di aver venduto un totale di 350.45K azioni del valore di $30.95M, nel frattempo, gli addetti ai lavori hanno segnalare nessun acquisto negli ultimi 30 giorni.
Notevoli acquisti e vendite recenti di insider
- Il giorno giugno 16, 2025, Meredith Cook, l'azienda SR. VP, GENERAL COUNSEL & SEC. sold 400 condivisioni per $61.37 ciascuna.
- Il giorno luglio 14, 2025, Meredith Cook, l'azienda SR. VP, GENERAL COUNSEL & SEC. sold 400 condivisioni per $64.88 ciascuna.
- Il giorno agosto 14, 2025, Meredith Cook, l'azienda SR. VP, GENERAL COUNSEL & SEC. sold 400 condivisioni per $88.87 ciascuna.
Statistiche sulla proprietà per ANI Pharmaceuticals Inc
Numero di azioni emesse
21.689M
Azioni possedute dagli insider
2.956M
Percentuale posseduta dagli Insider
13.7%
Azioni possedute dagli investitori istituzionali
11.158M
Percentuale posseduta dagli investitori istituzionali
51.4%
Aug 22, 2025 | HEAD OF R&D, COO-NOVITIUM OPS | -100.00K | $90.36 | -$9.04M | SELL | -18.62% | 436.92K | Aug 20 - Aug 21 | ||
Aug 20, 2025 | DIRECTOR | -21.54K | $89.15 | -$1.92M | SELL | -47.93% | 23.41K | Aug 18 | ||
Aug 20, 2025 | DIRECTOR | -5.42K | $89.73 | -$486.43K | SELL | -15.33% | 29.95K | Aug 20 | ||
Aug 18, 2025 | DIRECTOR | -6.94K | $88.17 | -$611.64K | SELL | -42.48% | 9.39K | Aug 18 | ||
Aug 18, 2025 | DIRECTOR | -9.00K | $89.05 | -$801.45K | SELL | -11.39% | 70.05K | Aug 15 | ||
Aug 18, 2025 | HEAD OF R&D, COO-NOVITIUM OPS | -100.00K | $88.25 | -$8.82M | SELL | -15.70% | 536.92K | Aug 14 - Aug 15 | ||
Aug 18, 2025 | SVP - CORP. DEV. & STRATEGY | -20.00K | $86.97 | -$1.74M | SELL | -7.50% | 246.84K | Aug 15 | ||
Aug 14, 2025 | SVP, HEAD - ESTABLISHED BRANDS | -4.97K | $85.71 | -$426.41K | SELL | -10.87% | 40.79K | Aug 12 | ||
Aug 14, 2025 | PRESIDENT & CEO | -56.96K | $85.93 | -$4.89M | SELL | -12.17% | 411.22K | Aug 12 | ||
Aug 14, 2025 | SVP, GENERICS | -5.87K | $86.53 | -$508.19K | SELL | -6.53% | 84.02K | Aug 12 | ||
Aug 14, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $88.87 | -$35.55K | SELL | -0.52% | 76.47K | Aug 13 | ||
Aug 14, 2025 | SVP & CFO | 0.00 | $66.28 | -$1.98M | SELL-OPTIONS | 0.00% | 180.86K | Aug 12 | ||
Aug 14, 2025 | DIRECTOR | -19.34K | $85.93 | -$1.66M | SELL | -34.62% | 36.52K | Aug 12 | ||
Jul 14, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $64.88 | -$25.95K | SELL | -0.50% | 78.94K | Jul 14 | ||
Jun 16, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $61.37 | -$24.55K | SELL | -0.50% | 79.34K | Jun 13 | ||
May 16, 2025 | SVP, GENERICS | -881.00 | $60.07 | -$52.92K | SELL | -0.97% | 89.90K | May 15 | ||
May 15, 2025 | HEAD OF RARE DISEASE | -4.00K | $60.45 | -$241.80K | SELL | -3.59% | 107.32K | May 14 | ||
May 13, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $62.20 | -$24.88K | SELL | -0.50% | 79.75K | May 13 | ||
May 13, 2025 | HEAD OF R&D, COO-NOVITIUM OPS | -700.00 | $76.83 | -$53.78K | SELL | -0.11% | 636.92K | May 09 | ||
Apr 14, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $68.96 | -$27.58K | SELL | -0.50% | 80.14K | Apr 14 | ||
Mar 20, 2025 | SVP, CHIEF HR OFFICER | -1.87K | $65.00 | -$121.29K | SELL | -2.80% | 64.66K | Mar 19 | ||
Mar 14, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $63.33 | -$25.33K | SELL | -0.49% | 80.55K | Mar 13 | ||
Mar 10, 2025 | SVP, CHIEF HR OFFICER | -1.00K | $60.86 | -$60.86K | SELL | -1.48% | 66.53K | Mar 07 | ||
Mar 07, 2025 | SVP, GENERICS | -5.08K | $45.75 | -$313.60K | SELL | -5.13% | 94.09K | Mar 05 | ||
Feb 24, 2025 | SVP, CHIEF HR OFFICER | -1.00K | $60.20 | -$60.20K | SELL | -1.44% | 68.62K | Feb 21 | ||
Feb 18, 2025 | SR. VP, GENERAL COUNSEL & SEC. | 26.46K | $59.06 | -$108.31K | GRANT | 47.59% | 82.04K | Feb 12 - Feb 14 | ||
Jan 13, 2025 | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $53.92 | -$21.57K | SELL | -0.71% | 55.59K | Jan 13 | ||
Dec 18, 2024 | SVP & CFO | -7.50K | $55.79 | -$418.43K | SELL | -4.63% | 154.47K | Dec 17 | ||
Dec 16, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.24 | -$14.06K | SELL | -0.44% | 55.99K | Dec 13 | ||
Dec 12, 2024 | SVP, CHIEF HR OFFICER | -1.00K | $60.00 | -$60.00K | SELL | -2.00% | 49.06K | Dec 11 | ||
Nov 27, 2024 | PRESIDENT & CEO | -3.48K | $43.49 | -$1.07M | SELL | -0.93% | 370.38K | Nov 26 | ||
Nov 18, 2024 | HEAD OF RARE DISEASE | -6.50K | $57.70 | -$375.05K | SELL | -7.81% | 76.78K | Nov 15 | ||
Nov 14, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $61.36 | -$15.34K | SELL | -0.44% | 56.24K | Nov 13 | ||
Oct 15, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $57.19 | -$14.30K | SELL | -0.44% | 56.49K | Oct 14 | ||
Sep 16, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.82 | -$14.21K | SELL | -0.44% | 56.74K | Sep 13 | ||
Aug 14, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $59.62 | -$14.90K | SELL | -0.44% | 56.99K | Aug 13 | ||
Jul 19, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -2.74K | $62.00 | -$170.07K | SELL | -0.43% | 637.62K | Jul 18 | ||
Jul 17, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -47.26K | $63.73 | -$3.01M | SELL | -6.87% | 640.36K | Jul 15 - Jul 17 | ||
Jul 15, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $64.91 | -$16.23K | SELL | -0.42% | 58.98K | Jul 12 | ||
Jul 02, 2024 | SVP - CORP. DEV. & STRATEGY | -20.00K | $63.44 | -$1.27M | SELL | -7.61% | 242.91K | Jul 01 | ||
Jun 24, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -20.00K | $58.90 | -$1.18M | SELL | -2.83% | 687.62K | Jun 21 | ||
Jun 20, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -30.00K | $60.59 | -$1.82M | SELL | -4.07% | 707.62K | Jun 17 - Jun 20 | ||
Jun 14, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $63.80 | -$15.95K | SELL | -0.42% | 59.23K | Jun 13 | ||
Jun 06, 2024 | SVP, GENERICS | -2.98K | $67.00 | -$200.00K | SELL | -3.72% | 77.23K | Jun 05 | ||
Jun 06, 2024 | SVP & CFO | -5.00K | $63.58 | -$317.90K | SELL | -2.99% | 161.97K | Jun 04 | ||
Jun 04, 2024 | SVP - CORP. DEV. & STRATEGY | -20.00K | $64.41 | -$1.29M | SELL | -7.07% | 262.90K | Jun 03 | ||
May 22, 2024 | HEAD OF RARE DISEASE | -2.00K | $61.61 | -$123.22K | SELL | -2.35% | 83.28K | May 21 | ||
May 21, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -12.86K | $61.81 | -$794.57K | SELL | -1.71% | 737.62K | May 20 | ||
May 17, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -37.15K | $64.37 | -$2.39M | SELL | -4.72% | 750.48K | May 15 - May 17 | ||
May 17, 2024 | DIRECTOR | -2.00K | $63.87 | -$127.74K | SELL | -9.90% | 18.21K | May 16 | ||
May 16, 2024 | PRESIDENT & CEO | -16.67K | $66.10 | -$1.10M | SELL | -4.23% | 377.50K | May 14 | ||
May 13, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $67.69 | -$16.92K | SELL | -0.42% | 59.48K | May 13 | ||
May 03, 2024 | SVP - CORP. DEV. & STRATEGY | -20.00K | $66.62 | -$1.33M | SELL | -6.60% | 282.90K | May 01 | ||
Apr 22, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -27.23K | $65.10 | -$1.77M | SELL | -3.34% | 787.62K | Apr 18 - Apr 19 | ||
Apr 17, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -22.77K | $65.91 | -$1.50M | SELL | -2.72% | 814.85K | Apr 15 - Apr 17 | ||
Apr 15, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $67.79 | -$16.95K | SELL | -0.42% | 59.73K | Apr 12 | ||
Apr 02, 2024 | SVP - CORP. DEV. & STRATEGY | -20.00K | $67.25 | -$1.34M | SELL | -6.19% | 302.90K | Apr 01 | ||
Mar 13, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $66.54 | -$16.64K | SELL | -0.42% | 59.98K | Mar 13 | ||
Mar 13, 2024 | SVP - CORP. DEV. & STRATEGY | -20.00K | $65.81 | -$1.32M | SELL | -5.83% | 322.90K | Mar 11 | ||
Mar 11, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -10.00K | $67.17 | -$671.70K | SELL | -1.18% | 837.62K | Mar 08 | ||
Mar 11, 2024 | SVP & CFO | -12.00K | $65.96 | -$791.69K | SELL | -6.33% | 177.71K | Mar 07 - Mar 11 | ||
Mar 08, 2024 | PRESIDENT & CEO | -62.32K | $66.27 | -$4.13M | SELL | -13.15% | 411.63K | Mar 06 - Mar 08 | ||
Mar 07, 2024 | SVP OPS & PROD DEV | -26.37K | $66.40 | -$1.75M | SELL | -17.72% | 122.46K | Mar 07 | ||
Mar 07, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -40.00K | $65.77 | -$2.63M | SELL | -4.51% | 847.62K | Mar 05 - Mar 07 | ||
Mar 06, 2024 | HEAD OF RARE DISEASE | -5.00K | $66.00 | -$330.00K | SELL | -5.41% | 87.39K | Mar 05 | ||
Mar 06, 2024 | DIRECTOR | -7.00K | $65.20 | -$456.40K | SELL | -20.82% | 26.63K | Mar 04 | ||
Feb 13, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.04 | -$14.01K | SELL | -0.67% | 36.80K | Feb 13 | ||
Jan 23, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -25.22K | $56.17 | -$1.42M | SELL | -2.76% | 887.62K | Jan 19 - Jan 23 | ||
Jan 18, 2024 | HEAD OF R&D, COO-NOVITIUM OPS | -24.78K | $55.29 | -$1.37M | SELL | -2.64% | 912.84K | Jan 16 - Jan 18 | ||
Jan 16, 2024 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.43 | -$14.11K | SELL | -0.67% | 37.05K | Jan 12 | ||
Dec 19, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $52.55 | -$2.63M | SELL | -5.06% | 937.62K | Dec 15 - Dec 19 | ||
Dec 11, 2023 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $49.21 | -$12.30K | SELL | -0.67% | 37.30K | Dec 11 | ||
Nov 20, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -13.00K | $51.00 | -$663.00K | SELL | -1.30% | 987.62K | Nov 17 | ||
Nov 16, 2023 | SVP, CHIEF HR OFFICER | -2.62K | $53.81 | -$141.09K | SELL | -7.45% | 32.59K | Nov 15 | ||
Nov 16, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -36.19K | $53.00 | -$1.92M | SELL | -3.49% | 1.00M | Nov 14 - Nov 16 | ||
Nov 14, 2023 | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $52.03 | -$13.01K | SELL | -0.66% | 37.55K | Nov 13 | ||
Nov 13, 2023 | HEAD OF RARE DISEASE | -3.00K | $52.47 | -$157.41K | SELL | -4.50% | 63.61K | Nov 10 | ||
Oct 19, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -25.00K | $57.75 | -$1.44M | SELL | -2.35% | 1.04M | Oct 17 - Oct 19 | ||
Oct 17, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -25.00K | $57.96 | -$1.45M | SELL | -2.30% | 1.06M | Oct 13 - Oct 16 | ||
Oct 03, 2023 | SVP - CORP. DEV. & STRATEGY | -20.00K | $56.48 | -$1.13M | SELL | -5.84% | 322.17K | Oct 02 | ||
Sep 19, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $61.81 | -$3.09M | SELL | -4.40% | 1.09M | Sep 15 - Sep 19 | ||
Sep 05, 2023 | SVP - CORP. DEV. & STRATEGY | -20.00K | $64.70 | -$1.29M | SELL | -5.52% | 342.17K | Sep 01 | ||
Aug 30, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $63.22 | -$3.16M | SELL | -4.21% | 1.14M | Aug 28 - Aug 29 | ||
Aug 25, 2023 | SVP, GENERICS | -2.06K | $46.94 | -$545.67K | SELL | -3.27% | 60.91K | Aug 23 | ||
Aug 25, 2023 | SVP OPS & PROD DEV | 1.49K | $50.63 | -$40.49K | SELL-OPTIONS | 1.13% | 133.11K | Aug 23 | ||
Aug 16, 2023 | 10% OWNER | -200.00K | $58.50 | -$11.70M | SELL | -9.90% | 1.82M | Aug 16 | ||
Aug 16, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $61.35 | -$3.07M | SELL | -4.04% | 1.19M | Aug 14 - Aug 15 | ||
Aug 16, 2023 | SVP & CFO | -17.64K | $61.37 | -$1.08M | SELL | -10.17% | 155.84K | Aug 14 | ||
Aug 15, 2023 | DIRECTOR | -3.00K | $60.37 | -$181.11K | SELL | -8.19% | 33.63K | Aug 14 | ||
Aug 15, 2023 | PRESIDENT & CEO | -56.67K | $43.66 | -$3.65M | SELL | -13.82% | 353.39K | Aug 11 - Aug 15 | ||
Aug 03, 2023 | SVP - CORP. DEV. & STRATEGY | -20.00K | $51.06 | -$1.02M | SELL | -5.23% | 362.17K | Aug 01 | ||
Jul 21, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -23.47K | $52.02 | -$1.22M | SELL | -1.86% | 1.24M | Jul 19 - Jul 21 | ||
Jul 18, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -26.53K | $51.02 | -$1.35M | SELL | -2.06% | 1.26M | Jul 14 - Jul 18 | ||
Jul 06, 2023 | SVP - CORP. DEV. & STRATEGY | -20.00K | $53.43 | -$1.07M | SELL | -4.97% | 382.17K | Jul 03 | ||
Jun 23, 2023 | SVP - CORP. DEV. & STRATEGY | -20.00K | $51.32 | -$1.03M | SELL | -4.74% | 402.17K | Jun 22 | ||
Jun 22, 2023 | HEAD OF R&D, COO-NOVITIUM OPS | -40.00K | $51.75 | -$2.07M | SELL | -76.33% | 12.41K | Jun 20 - Jun 22 | ||
Dec 02, 2022 | DIRECTOR | -200.00K | $38.50 | -$7.70M | SELL | -9.01% | 2.02M | Dec 01 | ||
Aug 16, 2022 | SVP OPS & PROD DEV | -18.07K | $37.26 | -$673.07K | SELL | -13.31% | 117.64K | Aug 12 - Aug 15 | ||
Mar 23, 2022 | PRESIDENT & CEO | 7.22K | $27.69 | $200.00K | BUY | 4.45% | 169.65K | Mar 21 | ||
Mar 22, 2022 | — | 5.00K | $27.76 | $138.79K | BUY | 10.33% | 53.39K | Mar 21 | ||
Mar 22, 2022 | SVP - CORP. DEV. & STRATEGY | 10.00K | $27.51 | $275.09K | BUY | 2.61% | 393.23K | Mar 18 - Mar 21 | ||
Mar 21, 2022 | HEAD OF R&D, COO-NOVITIUM OPS | 10.00K | $27.65 | $276.50K | BUY | 0.75% | 1.34M | Mar 17 | ||
Dec 22, 2021 | — | 1.07K | $46.47 | $49.82K | BUY | 6.41% | 17.79K | Dec 20 | ||
Dec 09, 2021 | — | 3.00K | $42.26 | $126.79K | BUY | 17.95% | 19.71K | Dec 07 | ||
Dec 07, 2021 | — | 2.50K | $39.38 | $98.45K | BUY | 9.02% | 30.20K | Dec 06 | ||
Mar 17, 2021 | — | 4.00K | $32.89 | $131.56K | BUY | 11.40% | 39.10K | Mar 15 | ||
Nov 12, 2020 | — | 5.00K | $25.96 | $129.80K | PURCHASE | 16.61% | 35.10K | Nov 09 |
FAQ
L'insider trading è legale?
L'insider trading è legale a condizione che gli insider segnalino le loro operazioni alla SEC. Il trading illegale di titoli si verifica quando l'insider viola un dovere fiduciario o non segnala le sue operazioni.
Quali sono alcuni esempi di manipolazione del mercato?
L'insider trading, gli schemi di pump and dump, il front running e i wash trade sono tutti esempi di manipolazione del mercato. Gli investitori che seguono i movimenti delle attività degli insider dovrebbero riflettere attentamente sul motivo per cui questi insider stanno negoziando le loro azioni prima di procedere.
Sfoglia insider trading su tutte le azioni.